Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | MYC | P01106 | 16/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | GLA | P06280 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834351 | 1.00 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17834332 | 0.89 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17834257 | 0.89 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17834252 | 0.88 | MEN1 (0.79) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17821432 | 0.88 | MYC (0.84) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17821427 | 0.88 | MYC (0.84) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17834249 | 0.87 | MYC (0.78) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17834346 | 0.87 | MYC (0.86) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17821372 | 0.87 | MYC (1.00) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17821374 | 0.87 | MYC (1.00) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-02-13 | — | — | US | disclosed |
| US-10017520-B2 | Myc modulators and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2016094688-A1 | FUSED 1,3-AZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168165-A1 | MYC MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168165-A1 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | MEN1 336/4885KMT2A 1253/4885SMN1; SMN2 4149/4885 |
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | MEN1 336/4885KMT2A 1253/4885SMN1; SMN2 4149/4885 |
| US-10017520-B2 | Myc modulators and uses thereof | MYC, MYCBP, MYCBP2 | MEN1 336/4885KMT2A 1253/4885SMN1; SMN2 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.